Ground Report | New Delhi: Roche India and Cipla announced the launch of their antibody cocktail – ‘Casirivimab and Imdevimab’ for the treatment of mildly infected patients of Covid-19 in India. The first batch of antibody cocktail is made available in India and is priced at Rs 59,750 per dose. At the same time another batch will be available in India by June.
Cipla and Roche said in a joint release, “In total they could potentially benefit 200,000 patients as there are 100,000 packs available in India. One pack provides treatment for two patients. The drug is available in major hospitals and COVIDs. Will be available through treatment centers.”
Cipla and Roche said in a joint statement that the Antibody cocktail is now available in India. Its second shipment will be able to arrive in the country by the middle of June. In total, it can treat 2,00,000 infected patients. Two patients can be treated in a pack of 1,00,000 packs.
This cocktail drug Casirivimab and Imdevimab developed by Roche has been approved for emergency use in India. According to the Ministry of Health, the Central Drugs Standard Control Organization (CDSCO) inspected the data for this antibody drug in the wake of the Corona epidemic. Let us tell you that its emergency use was approved in the US as well.
How much to pay for an antibody cocktail?
The combined dose of this drug (600 mg of Casirivimab and 600 mg of Imdevimab) for each patient has been fixed at Rs 59,750 for 1,200 mg. The multidose pack of this drug is priced at Rs 1,19,500, which can be said to be much higher in terms of the common man. According to the report, the drug will be available in all major hospitals and covid treatment centers.
This cocktail drug of Roche Company can be used to treat mild and moderate corona virus-infected patients in adults and pediatric patients (12 years of age or older, weighing at least 40 kg). The use of these medicines reduces the risk of patients.